#United States #biopharmaceuticals #Tampa #ACCESS Forum #Most-Favored-Nation

The Ripple Effect of Most-Favored-Nation Pricing in Biopharma

In a rapidly evolving landscape, the World ACCESS Consortium (WAC) has unveiled significant findings regarding the implications of Most-Favored-Nation (MFN) pricing in the United States on the biopharmaceutical industry's strategies for global launches. The white paper, titled "The MFN Ripple Effect: An Evaluation of Biopharmaceutical Companies Navigating Most-Favored-Nation Pricing", synthesizes insights from a confidential survey of 16 pharmaceutical manufacturers, five executive interviews, and a comprehensive review of the existing policies and pricing strategies in the U.S. and globally.

Key Findings

One of the pivotal results from the research indicates a notable shift in how companies approach launch sequencing and global pricing governance under the MFN pricing initiative. The data, according to the survey, illustrated that:

• - Launch Sequencing Changes: 81% of manufacturers flagged the EU5 market as a potential risk for delayed launch for at least one pipeline product.
• - Increased Centralization: 69% reported tighter governance in global pricing structures, indicating a trend towards more centralized decision-making in the wake of U.S. pricing changes.
• - Higher Evidence Requirements: 75% indicated a growing necessity for robust evidence to support pricing claims, suggesting an increase in rigor surrounding health economics and outcomes research (HEOR).

Interestingly, however, only 38% of respondents reported increased investment in HEOR or real-world evidence, exposing a gap in resources despite the heightened expectations for evidence supporting pricing justification.

Rethinking Traditional Strategies

Ruslan Horblyuk, the lead author of the white paper, emphasized that the MFN pricing strategy is not an impediment but rather a catalyst for companies to reassess their established launch strategies. Even though uncertainty typically breeds caution, in this case, it has led to more aggressive re-evaluations of pricing and market access strategies.

Eric Faulkner, Executive Director of WAC, reiterated that the MFN pricing connects U.S. pricing decisions with global launch strategies, indicating that firms are not stepping back but redefining their approach on a case-by-case basis.

Implications for Market Access

As companies navigate this change, the implications for patient access to innovative treatments are profound. The research suggests that the impacts of MFN pricing policies won't be universal; they may disproportionately affect smaller and lower-cost markets and patients with rare diseases, thus potentially widening the access divide in healthcare innovation.

Joe Boswell, President of the ACCESS Forum, underscored the importance of relying on shared evidence rather than anecdotal reports, stating that the findings from the survey provide a necessary collective baseline for stakeholders as the MFN landscape continues to evolve.

Future Directions

Looking ahead, the focus on MFN's influence over launch sequencing and pricing strategies will be crucial at the upcoming ACCESS Forum US '27, set for February 16-18, 2027, in Miami. This gathering aims to address the implications of these findings in more detail and provide an executive course pre-forum focused on these changes.

In conclusion, the World ACCESS Consortium’s white paper serves as an essential tool for biopharmaceutical companies to adapt and strategically approach new challenges posed by U.S. MFN pricing. As the market continues to evolve, stakeholders are urged to stay informed on these pivotal shifts that could redefine biopharma market access and pricing strategies worldwide.